Biotech Values

[DewDiligence]

Medivir plans all-oral phase-2a trial of TMC435+TMC647055 (a non-nuke) in genotype-1 HCV:

http://finance.yahoo.com/news/medivir-phase-iia-interferon-free-064000688.html

Simeprevir [a/k/a TMC435], TMC647055 and low-dose ritonavir will be co-administered once daily, with and without ribavirin.

Approximately 40 patients will be enrolled in this study, which is divided in two parts. The first part will include patients chronically infected with HCV genotype-1, who are either treatment-naive or have relapsed after prior pegylated interferon (PegIFN)/ribavirin treatment. The treatment will consist of simeprevir, TMC647055 and low-dose ritonavir, with and without ribavirin for 12 weeks.

The second part of the trial will investigate the same regimen in prior null responder patients chronically infected with HCV genotype 1a.